Pharmacological characterization of FR194921, a new potent, selective, and orally active antagonist for central adenosine A1 receptors

Journal of Pharmacological Sciences

Volumn 96, Issue 1, 2004, Pages 42-52

  Maemoto, Takuya ^a   Tada, Miho ^a   Mihara, Takuma ^a   Ueyama, Noriko ^a   Matsuoka, Hideaki ^a   Harada, Katsuya ^a   Yamaji, Takayuki ^a   Shirakawa, Kiyoharu ^a   Kuroda, Satoru ^a   Akahane, Atsushi ^a   Iwashita, Akinori ^a   Matsuoka, Nobuya ^a   Mutoh, Seitaro ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Adenosine A1 receptor; Anxiety; Depression; Hypolocomotion; Memory deficit

Indexed keywords

2 (1 METHYL 4 PIPERIDINYL) 6 (2 PHENYLPYRAZOLO[1,5 A]PYRIDIN 3 YL) 3(2H) PYRIDAZINONE; 2 CHLORO N6 (3 IODOBENZYL) 9 [5 (METHYLCARBAMOYL) BETA DEXTRO RIBOFURANOSYL]ADENINE; 2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 6 N CYCLOPENTYLADENOSINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENINE NUCLEOTIDE DERIVATIVE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR; ADENOSINE A3 RECEPTOR; FR 194921; NEW DRUG; SCOPOLAMINE; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ANXIETY; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DEMENTIA; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG PENETRATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; ELEVATED PLUS MAZE TEST; FORCED SWIMMING TEST; HYPOLOCOMOTION; LIGAND BINDING; MALE; MAZE TEST; MEMORY DISORDER; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; PASSIVE AVOIDANCE; PASSIVE AVOIDANCE TEST; PHARMACOLOGICAL BLOCKING; RAT; RECEPTOR AFFINITY; RECEPTOR BLOCKING; SPECIES DIFFERENCE; TRANQUILIZING ACTIVITY;

EID: 4844220231     PISSN: 13478613     EISSN: None     Source Type: Journal    
DOI: 10.1254/jphs.FP0040359     Document Type: Article

References (43)

1. Fredholm BB, Abbracchio MA, Burnstock G, Bubyak GR, Harden TK, Jacobson KA, et al. Nomenclature and classification of purinoreceptors. Pharmacol Rev. 1994;46:143-156.
2. Palmer TM, Stiles GL. Neurotransmitter receptors VII: Adenosine receptors. Neuropharmacology. 1995;34:683-694.
3. Matsuoka I, Ohkubo S. ATP- and adenosine-mediated signaling in the central nervous system: adenosine receptor activation by ATP through rapid and localized generation of adenosine by ecto-nucleotidases. J Pharmacol Sci. 2004;94:95-99.
4. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev. 1998;50:413-492.
5. 1 receptors and 5′-nucleotidase in the brain of some commonly used experimental animals. Neuroscience. 1987;22:813-826.
6. 1 receptor in anesthetized monkey brain. Nucl Med Biol. 2000;27:401-406.
7. 11C]MPDX. Ann Nucl Med. 2003;17:511-515.
8. 1 receptors are located predominantly on axons in the rat hippocampal formation. J Comp Neurol. 1995;363:517-531.
9. 1 receptors in nerve terminals and synapses of the rat hippocampus. Brain Res. 2003;987:49-58.
10. Shan HQ, Cheng JS. Effect of adenosine on adenosine triphosphate- sensitive potassium channel during hypoxia in rat hippocampal neurons. Neurosci Lett. 2000;286:45-48.
11. 2+ channel subtypes in acutely isolated rat basolateral amygdala neurons. Br J Pharmacol. 2001;132:879-888.
12. 1 receptor. Eur J Pharmacol. 1997;340:301-310.
13. Dunwiddie TV. The physiological role of adenosine in the central nervous system. Int Rev Neurobiol. 1985;27:63-139.
14. 1 receptors. J Pharmacol ExpTher. 2002;303:356-363.
15. 1 receptor. J Pharmacol Exp Ther. 1995;273:637-642.
16. 3H]GABA release in slices of substantia nigra pars reticulata and motor behavior in the rat. Neuroscience. 2002;115:743-751.
17. Solinas M, Ferre S, You ZB, Karcz-Kubicha M, Popoli P, Goldberg SR. Caffeine induces dopamine and glutamate release in the shell of the nucleus accumbens. J Neurosci. 2002;22:6321-6324.
18. 1 receptor antagonist B1IP 20 counteracts scopolamine-induced behavioral deficits in the passive avoidance task in the rat. Eur J Pharmacol. 1997;328:19-22.
19. Gatch MB, Wallis CJ, Lal H. The effects of adenosine ligands R-PIA and CPT on ethanol withdrawal. Alcohol. 1999;19:9-14.
20. 1 receptor pharmacology revealed by use of xanthine and pyrazolopyridine based antagonists. Br J Pharmacol. 1997;122:1202-1208.
21. 1 receptors, using in vivo and in vitro techniques. J Pharmacol Exp Ther. 1998;285:1023-1030.
22. 1 receptor antagonists with high blood-brain barrier permeability. Chem Pharm Bull (Tokyo). 2001;49:988-998.
23. Chen C, Okayama H. High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol. 1987;7:2745-2752.
24. Matsuoka N, Maeda N, Yamazaki M, Ohkubo Y, Yamaguchi I. Effect of FR121196, a novel cognitive enhancer, on the memory impairment of rats in passive avoidance and radial arm maze tasks. J Pharmacol Exp Ther. 1992;263:436-444.
25. Porsolt RD, Anton G, Blavet N, Jalfre M. Behavioral despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol. 1978;47:379-391.
26. Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunctions. Science. 1982;217:408-414.
27. de Mendonca A, Ribeiro JA. Adenosine and neuronal plasticity. Life Sci. 1997;60:245-251.
28. Sebastiao AM, Ribeiro JA. Fine-tuning neuromodulation by adenosine. Trends Pharmacol Sci. 2000;21:341-347.
29. 1 receptors. Brain Res Bull. 1991;27:101-104.
30. Coffin VL, Carney JM. Behavioral Pharmacology of adenosine analogs. In: Daly JW, Kuroda Y, Phillis JM, Shimizu H, Ui M, editors. Physiology and pharmacology of adenosine derivatives. New York: Raven Press; 1983. p. 267-274.
31. 6-((R)-phenyl-isopropyl) adenosine-induced cognitive disturbance. J Med Chem. 1993;36:2508-2518.
32. Schignitz G, Kufner-Muhl U, Ensinger H, Lehr E, Kuhn FL. A novel xanthine derivative for treatment of cognitive deficits. Biol Psychiatry. 1991;29:694S.
33. 1 receptors in rat hippocampus is N-methyl-D-aspartate receptor-dependent. Neurosci Lett. 2000;291:81-84.
34. 1 receptor-mediated impairment of passive avoidance performance and long-term potentiatiom in the hippocampus. Biol Pharm Bull. 2001;24:496-500.
35. Bender AS, Phillis JW, Wu PH. Diazepam and flurazepam inhibit adenosine uptake by rat brain synaptosomes. J Pharm Pharmacol. 1980;32:293-294.
36. Moser PC. Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced head-twitches by diazepam. Evidence for involvement of adenosine uptake inhibition. Drug Dev Res. 1993;30:213-218.
37. Kaplan GB, Cotreau MM, Greenblatt DJ. Effects of benzodiazepine administration on A1 adenosine receptor binding in vivo and ex-vivo. J Pharm Pharmacol. 1992;44:700-703.
38. Zangrossi H Jr, Leite JR, Graeff FG. Anxiolytic effect of carbamazepine in the elevated plus-maze: possible role of adenosine. Psychopharmacology (Berl). 1992;106:85-89.
39. Hogg S. A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacol Biochem Behav. 1996;54:21-30.
40. Jain N, Kemp N, Adeyemo O, Buchanan P, Stone TW. Anxiolytic activity of adenosine receptor activation in mice. Br J Pharmacol. 1995;116:2127-2133.
41. 1 receptor. Proc Natl Acad Sci USA. 2001;98:9407-9412.
42. 2A receptor knockout mice. Br J Pharmacol. 2001;134:68-77.
43. 2A receptors and depression. Neurology. 2003;61:S82-S87.